Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671423 · ClinicalTrials.gov registry record · NA
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
A NA study of Cellulitis, sponsored by Albert Einstein Healthcare Network.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01671423: Completed NA study of Cellulitis, sponsored by Albert Einstein Healthcare Network.
NCT01671423 is a NA study of Cellulitis that has completed, run by Albert Einstein Healthcare Network. The registered enrollment target is 42 participants, below the 567-participant average among 11 other Cellulitis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01671423, a NA study of Cellulitis, has completed, sponsored by Albert Einstein Healthcare Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Cellulitis is the medical term for an infection of the skin, with symptoms including redness, swelling, warmth, and pain. This group of symptoms is called inflammation, and is caused by the body's immune system responding to the infection. Standard care for cellulitis is using antibiotics to destroy the infection, but the inflammation can persist and cause a great deal of pain. The hypothesis of this study is that adding a single dose of an oral steroid (prednisone), which tempers the immune response, will reduce inflammation, reduce pain, and speed recovery. This hypothesis will be examined by recruiting a group of patients with cellulitis, and randomizing them to two sub-groups: one group will receive a dose of prednisone, while the other group will receive a placebo. Neither group will know what they received unless there is a problem. These subjects will be followed up at the 48 hour mark and the 7 day mark, and will have their results compared.
Primary Outcome
The level of pain as measured by a Visual Analog Scale(VAS) measured once at day 1 and once during the 48th hour follow-up visit. Minimum value 0, maximum value 100mm, higher scores corresponds to more pain/worse outcomes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisone
Study Locations (1)
Pennsylvania
- Albert Einstein Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-09 |
| Phase | NA |
What the finished NCT01671423 record still lists
NCT01671423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 567-participant average among 11 other Cellulitis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cellulitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01671423 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01671423 about?
NCT01671423 is a clinical study titled "Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis". Cellulitis is the medical term for an infection of the skin, with symptoms including redness, swelling, warmth, and pain. This group of symptoms is called inflammation, and is caused by the body's immune system responding to the infection. Standard care for cellulitis is using antibiotics to destroy...
What is the current status of trial NCT01671423?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2012-08. Estimated completion is 2015-09.
What conditions does trial NCT01671423 study?
This clinical trial studies the following conditions: Cellulitis.
What interventions are being tested in trial NCT01671423?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT01671423?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01671423 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01671423's enrollment target sits among peer trials
42 12th of 11 the lowest of 11 other Cellulitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cellulitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
ACTIVE NOT RECRUITING · NA
-
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
COMPLETED · NA
-
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
COMPLETED · Phase 2
-
Utility of Thermal Imaging in Diagnosis of Cellulitis for Lower Extremity Complaints in the Emergency Department
COMPLETED
-
Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
COMPLETED · Phase 4
-
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia